Top Stories
Zuckerberg's Biohub is combining new cell data with federal datasets to train AI models that can predict how cells respond to changes, helping researchers study disease and identify potential treatments.
The new approach could spare patients from undergoing invasive biopsies.
The French biotech will use PacBio's HiFi and Kinnex long-read RNA sequencing to generate data from over 10,000 samples.
The Amgen-backed startup is partnering with healthcare systems to use genetic testing and clinical data to identify patients for precision care and drug development.
The smartphone treatment beat a digital control in a 457-patient Phase III trial, with a statistically significant small-to-moderate effect on symptoms tied to motivation and pleasure.
Conference News
SCHENECTADY, NY, UNITED STATES, October 7, 2026 /EINPresswire.com/ — EndoSoft®, LLC today announced Argus CareFlow™, an AI-powered patient engagement platform created to streamline patient outreach, p...
- Clinical studies demonstrate MycoMEIA’s performance as a non-invasive aid to diagnose invasive aspergillosis, with 92% sensitivity in a case-control study –- PearlDX to present clinical data on Myco...
Screening tool expected to help free eye camps reach far more of the people who need cataract surgery.6-Oct-2026 at 9:30 PM EDT, by American Academy of Ophthalmology (AAO)Newswise — Since 1963, doctor...
An artificial intelligence system trained on more than 150,000 retinal images predicted which children's vision would deteriorate sharply within a year, offering ophthalmologists a chance to intervene...
Podium presentation by Co-Founder and Chief Research Officer Laura van ’t Veer introduces an AI-driven approach to MammaPrintTwo additional poster presentations from the FLEX StudyIRVINE, Calif. & AM...
